Medications
Semaglutide vs tirzepatide: an honest comparison
July 6, 2026 · 1 min read
The short answer
Semaglutide activates the GLP-1 receptor; tirzepatide activates GLP-1 and GIP. In trials, tirzepatide has averaged greater weight loss, including in head-to-head comparison, roughly one fifth of body weight versus mid-teens percent over about 72 weeks.
Averages are not verdicts: individual responses overlap heavily, side-effect profiles are similar, and access, price, and tolerability decide more real outcomes than the trial gap does.
What's the mechanistic difference?
Semaglutide is a single-receptor agonist: it amplifies the GLP-1 signal (appetite, stomach pace, insulin timing; the basics live in how GLP-1s work). Tirzepatide adds a second hormone, GIP, on top of GLP-1. The dual signal appears to deepen the metabolic effect, which is the leading explanation for its stronger trial averages.
What do the numbers actually say?
Across their pivotal programs, semaglutide at its weight-management dose averaged roughly mid-teens percent body-weight loss, while tirzepatide at higher doses averaged around a fifth of body weight. A head-to-head trial (SURMOUNT-5) confirmed the direction: tirzepatide averaged meaningfully more loss than semaglutide over the same period.
Two honest caveats. First, distributions overlap: plenty of individuals do better on semaglutide than the average tirzepatide user. Second, trial conditions (adherence support, titration discipline) flatter both drugs relative to messy real life.
Do side effects differ?
Less than the marketing suggests. Both lead with the same gut effects: nausea, constipation or diarrhea, fatigue in the early weeks, clustering after dose increases. Head-to-head, tolerability looked broadly comparable. Your response to one says little about your response to the other, and switching between them is a routine prescriber move when one fits poorly.
How do you actually choose?
- Access and price first. Insurance coverage, availability, and cost eliminate options before pharmacology gets a vote.
- History second. Semaglutide has the longer safety record and additional outcome labels; tirzepatide has the stronger average efficacy. Your prescriber weighs both against your profile.
- Response last, and empirically. Whichever you start, judge it on your own trend line after reaching a therapeutic dose, not on someone else's average.
That judgment needs data: dose days, weight trend, appetite, side effects. DoseLog keeps the record that makes a switch conversation factual instead of vibes, whichever medication you are on.
Questions people ask
Which causes more weight loss, semaglutide or tirzepatide?
On trial averages, tirzepatide: roughly a fifth of body weight at higher doses versus mid-teens percent for semaglutide, and a head-to-head trial confirmed the direction. Individual responses overlap heavily, so your own trend matters more than the averages.
Is tirzepatide's side-effect profile worse?
Broadly similar: both lead with gut effects that cluster after dose increases and fade with adaptation. Head-to-head data showed comparable tolerability. Individual experiences vary either way.
Can you switch from semaglutide to tirzepatide or back?
Yes, it is a routine prescriber-managed transition, usually starting the new medication at a low or middle step rather than the top dose. Poor fit with one does not predict poor fit with the other.
What's the difference between GLP-1 and GIP?
Both are gut hormones released around meals. Semaglutide amplifies only GLP-1; tirzepatide amplifies GLP-1 and GIP together, a dual action that appears to deepen average weight-loss effects.
References
- 1.Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes. SURPASS-2. NEJM 2021. Find on PubMed ↗
- 2.Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. STEP 1. NEJM 2021. Read on NEJM ↗
- 3.Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. SURMOUNT-1. NEJM 2022. Read on NEJM ↗
This article is general education, not medical advice. DoseLog is a tracking and reflection tool. Decisions about your medication, dose, and symptoms belong with a licensed clinician.
Keep reading